International Clinical Trial: Evaluate the anti-tumor efficacy and safety of platinum-based doublet chemotherapy combined with tislelizumab and voriconazole as neoadjuvant therapy in patients with resectable stage II-III non-small cell lung cancer (NSCLC) with pulmonary Aspergillus colonization: a prospective, exploratory, single-arm phase II clinical study

Geneva, Aug. 17 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129648) titled 'Evaluate the anti-tumor efficacy and safety of platinum-based doublet chemotherapy combined with tislelizumab and voriconazole as neoadjuvant therapy in patients with resectable stage II-III non-small cell lung cancer (NSCLC) with pulmonary Aspergillus colonization: a prospective, exploratory, single-arm phase II clinical study' on Aug. 7.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Jiangxi Cancer Hospital

Condition: non-small cell lung cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-10-31

Target Sample Size: Experimental Group:30;

Cou...